Fuso Pharmaceutical Industries, Ltd.
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 6 name spellings.
4
Ending by 2030
Jul 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 11, 2027The maintenance fee for ANTI-PD-L1 Antibody for Detecting PD-L1 (US 11,697,686) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
- 2 fees due Feb 4 to 15, 2027 · next Feb 4
- 1 fee due Apr 10, 2027The maintenance fee for Vector Including a Translation-Impaired Dihydrofolate Reductase Gene Cassette and Ubiquitously Acting Chromatin Opening Element (US 11,781,146) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
- 1 fee due Aug 4, 2027The maintenance fee for Indole Alkaloid Compound Having Immune Checkpoint Inhibitory Action (US 10,550,120) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
- 1 fee due Oct 28, 2027The maintenance fee for T-type calcium channel inhibitor (US 10,633,358) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,540,658 | Adenovirus vector In force · From the USPTO record | In force | From the USPTO record | |
| US 9,096,878 | Expression Vector for Producing Protein Derived from Foreign Gene in Large Quantity Using Animal Cells, and Use Thereof In force · High confidence | In force | High confidence | |
| US 8,383,595 | Peptide derivative and composition for promoting tear secretion comprising the same In force · From the USPTO record | In force | From the USPTO record | |
| US 8,586,327 | Detection of bacteria belonging to the genus Campylobacter by targeting cytolethal distending toxin In force · From the USPTO record | In force | From the USPTO record | |
| US 9,029,627 | Model animal for pregnancy-induced hypertension syndrome, and treatment method therefor In force · From the USPTO record | In force | From the USPTO record | |
| US 8,932,867 | High purity heparin and production method therefor In force · From the USPTO record | In force | From the USPTO record | |
| US 9,540,454 | High purity heparin and production method therefor In force · From the USPTO record | In force | From the USPTO record | |
| US 9,410,120 | Composition for embryo culture In force · From the USPTO record | In force | From the USPTO record | |
| US 11,160,286 | Method for producing disinfected liver In force · From the USPTO record | In force | From the USPTO record | |
| US 10,633,358 | T-type calcium channel inhibitor In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 27: 6 patents in force now held by others · 52 lapsed for an unpaid fee · 26 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 12 abandoned · 18 no status recorded